RxDoctor Payments Data

Talal Ghazal, MD

Interventional Pain Medicine · Arlington, VANPI 1700080520

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,905 of the $4,772 with a category attached, or 81.8%. 18 manufacturers reported payments, led by Medtronic at 41.0% of the total.

$4,772in general payments, 2019–2025

Across 154 payments — averaging $30.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Pacira Pharmaceuticals Incorporated$729
  • Relievant Medsystems, Inc.$494
  • Nevro Corp.$321
  • Boston Scientific$294
  • Abbott$206
  • plus $772 from 12 others
$243,680in research payments, 2019–2025

Across 84 payments — averaging $2900.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$244K

What the payments were for

  • Travel & lodging$86718%
  • Food & beverage$3,90582%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,772 in reported general payments places this provider in the 55th percentile of 52 interventional pain medicine providers in Virginia.

See all interventional pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$131,660
Medicare patients
242
Services billed
1,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fentanyl20$2,399
Duloxetine Hcl18$1,263
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$887
Gabapentin68$854
Oxycodone Hcl52$725
Pregabalin14$555
Diclofenac Sodium15$378
Tramadol Hcl72$367
Cyclobenzaprine Hcl17$288
Hydromorphone Hcl18$145

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →